Introduction Recent strategic maneuvers by Illumina, such as the disposal of Grail and the acquisition of Fluent Biosciences, have injected a bullish momentum into its stock. This narrative explores these pivotal moves, the macroeconomic context, the contradictory signals from the bearish put-call ratio, and the shifting analyst expectations. Strategic Moves: Grail Spin-off and Fluent Acquisition … Continue reading The Bullish Momentum of Illumina: A Turnaround Story